Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More
Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More
Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More
This is the latest episode of the free DDW podcast, “What does gene-based medicine have to offer?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW. The articles are called “Lipidomics in biomedical research: chance and challenges” and “Exploring gene-based medicine’s true potential”. Read More
Genome technology platform provider Jumpcode Genomics has launched technology to improve single cell transcriptional profiling and aid with scientists’ understanding of genomic sequences. Jumpcode Genomics’ CRISPRclean Single Cell RNA Boost Kit leverages the company’s CRISPR-based technology to remove uninformative sequences from libraries, enhancing single cell… Read More
DDW’s Megan Thomas spent March 1-2, 2022 at the fourth ‘CRISPR in Drug Discovery: From Targets to Therapeutics’, which took place at Babraham Research Campus in Cambridge, UK. Finding it insightful and eye-opening, she looks forward to the next event on ELRIG's agenda, ‘Research & Innovation’ at The Kings Centre… Read More
Listen to this article on the DDW Podcast: Rosie Bryan & Carlos le Sage, Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics. While efforts in the cancer genomics field have uncovered the mutational landscapes in tumours covering many types of cancer, the functional contribution of the mutated… Read More
Olivia Hughes from Sphere Fluidics discusses how advances in picodroplet microfluidics, combined with the high efficiency of CRISPR/Cas9 technology, are fuelling a new wave of innovation in the form of a simple click-through workflow for genome editing. Picodroplet microfluidics is rapidly becoming the technology of choice for high-throughput single cell analysis, providing an easy-to-use tool to… Read More
The latest free-to-listen DDW podcast episode is titled “Therapeutics: Changing the way we treat disease”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas. These articles are titled: “Avoiding double strand breaks on… Read More
Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More
The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering. The report features a study of the current market landscape and future opportunity for the players involved in the development of CRISPR… Read More
The National Institutes of Health (NIH) has awarded approximately $53 million in annual funding over the next five years to ten research organisations in a continued effort to find a cure for HIV. The new awards for the Martin Delaney Collaboratories for HIV Cure Research programme expand the initiative’s 2016 renewal from six institutions to ten. Read More
Listen to this article on the DDW Podcast: Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write this, vaccines… Read More
Macrophages are involved in many different disease states, so understanding more about how these cells are regulated is important for future therapies for a range of diseases. CD14, a co-receptor for bacterial lipopolysaccharide, and can potentiate inflammatory signalling when upregulated on myeloid cells during differentiation. Join DDW for this webinar,… Read More
Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward… Read More
Listen to this article on the DDW Podcast: Now a key pillar in the early stages of therapeutics development, the limitations of introducing a DNA double strand break mean that workflows are broadening away from CRISPR–Cas as a gene knockout technology and towards platforms that enable genetic modulation and safer genetic… Read More
